In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 diagnosed with mild to early-moderate Alzheimer's disease (AD) or mild cognitive impairment (MCI) and comorbid Major Depressive Disorder (MDD) who have been unable to tolerate or failed to respond to antidepressant medications. The coil was designed to stimulate deeper regions of the left dorsolateral prefrontal cortex (DLPFC). Based on prior research, the investigators propose that active stimulation with the H1 coil for 4 weeks may result in significant remission rates and will be tolerable and safe.
This study is an open-label trial to evaluate the safety and efficacy of H1-coil dTMS in treating depression in MCI and mild AD patients over 60 years of age who have not tolerated or failed to respond to antidepressant medications. 28 patients will be assigned to receive 4 consecutive weeks of daily active dTMS treatment. The long-term effects of treatment on emotional cognitive measures will be assessed at a 4-week follow-up visit (8 weeks from baseline). Symptom change and remission criteria will be assessed using the Montogmery-Asberg Depression Rating Scale (MADRS). Cognition will be assessed using a validated neuropsychological battery. We will also offer patients to receive 4 weeks of treatment using theta-burst TMS, which is a milder version of TMS.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
28
Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
Rotman Research Institute at Baycrest
Toronto, Ontario, Canada
RECRUITINGChange From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS)
Therapeutic efficacy will be evaluated with the MADRS, a 10-item checklist. An effect size (Cohen's d) of 0.5 will be considered a minimally important effect size.
Time frame: 4 weeks
Remission Rates Compared Within Treatment Group
Remission defined as MADRS \< 10.
Time frame: 4 weeks
Response Rates Compared Within Treatment Group
Response rate refers to the percentage of patients who responded to dTMS treatment and response is defined as a ≥50% reduction in MADRS score from baseline.
Time frame: 4 weeks
Change From Baseline on the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
This 16-item questionnaire is designed to help assess the degree of enjoyment and satisfaction experienced during the past week. Administration time is approximately 5 minutes.
Time frame: 4 weeks
Change From Baseline on the Neuropsychological Battery
Cognitive scores from the neuropsychological battery at baseline will be compared to 4 weeks post-intervention Cognitive domains tested include executive function, memory, language, attention, and intelligence.
Time frame: 4 weeks
Change in Functional Connectivity between PFC and Limbic Regions
Subjects will have magnetic resonance imaging (MRI) scans of the brain. The change in functional connectivity between PFC and limbic regions, and within the default mode network, at rest is measured using resting state fMRI.
Time frame: 4 weeks
Change in Perfusion within Prefrontal Cortex (PFC) and Posterior Cingulate Cortex (PCC)
Measured using Arterial Spin Labeling (ASL) fMRI scan.
Time frame: 4 weeks
Change in frontal theta power within the Anterior Cingulate Cortex (ACC)
Measured with electroencephalography (EEG) and/or magnetoencephalography (MEG).
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.